背景与目的:大多数关于骨质疏松药物作用的研究通过双能X线骨密度仪(DEXA)测量了脊柱和股骨的骨密度(BMD),并通过BMD值的变化比较和分析了药物的作用。本研究旨在通过从髋部骨折患者中获取股骨头,比较利塞膦酸盐治疗后骨细胞中破骨细胞和硬化蛋白的表达。材料和方法:我们获得了10名女性患者(年龄:≥65岁)的股骨头,这些患者在2019-2021年期间通过髋关节置换术接受了利塞膦酸盐治疗至少1年(利塞膦酸盐组)。同时,选择10例从未接受过骨质疏松症治疗的患者作为对照,使用年龄倾向评分,身体质量指数,和骨密度作为协变量(对照组)。虽然使用抗酒石酸酸性磷酸酶(TRAP)染色评估破骨细胞计数,使用免疫组织化学方法评估骨细胞中硬化蛋白的表达。此外,蛋白质印迹和聚合酶链反应(PCR)进行了核因子κ-Β配体(RANKL)的受体激活,RANK,骨保护素(OPG),硬化蛋白,和骨形态发生蛋白-2(BMP2)。结果:TRAP染色显示对照组的TRAP阳性细胞(131.75±27.16/mm2)明显多于利塞膦酸盐组(28.00±8.12/mm2)。此外,硬化蛋白阳性骨细胞在对照组中的表达(364.12±28.12/mm2)高于利塞膦酸钠组(106.93±12.85/mm2)。Western印迹显示RANKL的表达,RANK,硬化蛋白,对照组BMP2高于利塞膦酸钠组(p<0.05)。此外,RANK,硬化蛋白,对照组和OPG蛋白水平高于利塞膦酸钠组。结论:在这项研究中,利塞膦酸钠组股骨头破骨细胞活性和骨硬化蛋白表达低于对照组。
Background and Objectives: The majority of research on the effects of osteoporosis drugs has measured the bone mineral density (BMD) of the spine and femur through dual-energy X-ray absorptiometry (DEXA) and compared and analyzed the effects of the drugs through changes in the BMD values. This
study aims to compare osteoclast and sclerostin expression in
osteocytes after risedronate therapy by obtaining femoral heads from patients with hip fractures. Materials and Methods: We obtained the femoral heads of 10 female patients (age: ≥65 years) who received risedronate therapy for at least 1 year through hip arthroplasty during 2019−2021 (risedronate group). Meanwhile, 10 patients who had never received osteoporosis treatment were selected as controls using propensity scores with age, body mass index, and bone density as covariates (control group). While the osteoclast count was evaluated using tartrate-resistant acid phosphatase (TRAP) staining, the sclerostin expression in
osteocytes was assessed using immunohistochemistry. Moreover, Western blotting and polymerase chain reaction (PCR) were performed for receptor activation of nuclear factor kappa-Β ligand (RANKL), RANK, osteoprotegerin (OPG), sclerostin, and bone morphogenetic protein-2 (BMP2). Results: TRAP staining revealed significantly more TRAP-positive cells in the control group (131.75 ± 27.16/mm2) than in the risedronate group (28.00 ± 8.12/mm2). Moreover, sclerostin-positive
osteocytes were expressed more in the control group (364.12 ± 28.12/mm2) than in the risedronate group (106.93 ± 12.85/mm2). Western blotting revealed that the expressions of RANKL, RANK, sclerostin, and BMP2 were higher in the control group than in the risedronate group (p < 0.05). Furthermore, RANK, sclerostin, and OPG protein levels were higher in the control group than in the risedronate group. Conclusions: In this
study, the risedronate group demonstrated lower osteoclast activity and sclerostin expression in
osteocytes in the femoral head than the control group.